Myelodysplastic Syndrome - An underserved population offers commercial opportunity

Questions: Discounts, Updates etc.

Price: $1,900.00

Publication Date: 2005-10-18

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, the former's similar efficacy and toxicity to Pharmion's Vidaza, the first drug indicated for MDS, coupled with the limited target population of the Revlimid, will leave a significant proportion of the MDS population underserved by pharmacotherapy.


Scope

  • Overview of MDS epidemiology, classification and staging, prognosis and risk factors
  • Examination of unmet needs in MDS treatment and market opportunities for drug developers
  • Review of current treatment controversies and physician opinion of existing and future treatment strategies
  • Profile of the therapeutic and commercial potential of pipeline drugs


    • Report Highlights
    MDS can affect all ages but is predominantly found in the elderly, with the Aplastic Anemia & MDS International Foundation estimating that 80% of those affected are over 60 years of age. Consequently as a result of the elderly suffering more co-morbidities and poorer prognosis, the current treatment of MDS consists mainly of supportive care.

    In the years following Dacogen's anticipated US launch in 2006, Datamonitor predicts the sales margin between it and Vidaza will narrow as physicians gain familiarity with Dacogen and SuperGen/MGI Pharma establish more convenient dosing regimens. However, Vidaza is still predicted to maintain a market lead over its closest direct competitor.

    Recently recommended by the FDA's Advisory Committee for accelerated approval, Revlimid looks certain to enter the MDS market in 2006. Indicated for lower-risk MDS in the presence of a chromosome abnormality known as 5q-, Revlimid will quickly become the standard treatment in this patient cohort with additional off-label use also predicted.


    Reasons to Purchase

  • Understand current controversies in MDS treatment and adopt knowledge from this report to drive strategic planning for novel MDS therapeutics
  • Assess opportunities and risks for innovative treatments within the MDS market
  • Gain insight into current treatment paradigms, as reported by leading oncologists/ hematologists

    • Table of Contents

    Other users found this report page using the following search terms: myelodysplastic leukemia lymphoma dacogen mds vidaza price myelodysplastic syndrome prevalence revlimid treatment eu

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.